Last Update 30 07 2017
  • 21/10/2016
    FDA Approves Merck’s Zinplava (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection

  • 20/10/2016
    FDA Grants Accelerated Approval to Lartruvo (olaratumab) for Advanced Soft Tissue Sarcoma -

  • 19/01/2017
    FDA Approves Trulance (plecanatide) for Chronic Idiopathic Constipation

  • 31/01/2017
    Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma

  • 30/01/2017
    Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma

  • 08/02/2017
    FDA Approves Amgen's Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis

  • 09/02/2017
    FDA Approves Emflaza (deflazacort) to treat Duchenne Muscular Dystrophy

Equivamed was initiated in 2002 by Daniel Elbaze a senior pharmacist managing a pharmacy channel. Daniel is already famous in France for his international research.
The objective was to create a tool that will link between the DCI and the Drugs in any country in the world.
Feeling the huge demand for more countries to be referenced Daniel began an Ant work in a view to cover as many country as he could. Very quickly the infrastructure was not robust enough to support the stress. In 2008 T.T.C Ltd starts its collaboration with Daniel and equivamed that looks for marketing and technical solutions, rebuilding the old system to a brand new one bases on latest technology.
The intended audience of the site is health professionals, students and general public.
My site and its mirrors respect the legal requirements, including those concerning medical and personal information privacy, that apply in the country and state of their location.
The Sources of the site and its content comes directly from laboratory and medical authorities of each country .
Webmaster and editorial manager: Daniel ELBAZ
This site is for informational purposes only. Please note that a reasonable attempt is made to provide accurate information. The webmaster is not responsible for any error contained within. All persons should interpret the information with caution and should seek medical advice when necessary. I have not received money from companies that I display the link on the website ; "I certify my personal finance website"
  • More than 1.700.000 Drugs Name and 9550 DCI
  • A Daily update .
  • A Professional Double Check
  • Around 220 Included Countries
  • Japanese (日本), Chinese (中國), Hebrew (עברית), Thai (การบินไทย), Russian(русский),Greek (ελληνικά), Georgian (საქართველოს), Arabic (العربية) , korean (한국의),Armenian(հայերեն) ,Persian(فارسی), Hindi (हिंदी)
  • New countries added Lithuania, Tonga
  • Countries to be added soon

    • new product 香砂养胃丸
    • new product 十全大补丸
    • new product 杞菊地黄丸
    • new product エイムゲン
    • new product アブラキサン点滴静注用100mg
    • new product インデラル錠10mg、インデラル錠20mg
    • new product YERVOY (ipilimumab)
    • new product וימפט 50 מ"ג
    • new product פרג'טה
    • new product סיברי בריזהלר 50 מק"ג
    • new product אריוודג'
    • new product בייאטה 10 מק"ג
    • new product בייאטה 5 מק"ג
    • new product קפרלסה 100 מ"ג
    • new product Hetlioz (tasimelteon)
    • new product Vimizim (elosufase alfa)
    • new product Myalept (metreleptin)
    • new product Tivorbex (indomethacin)
    • new product Northera (droxidopa)
    • new product Otezla (apremilast)
    • new product Alprolix (coagulation factor IX (recombinant))
    • new product Evzio (naloxone hydrochloride)
    • new product Cyramza (ramucirumab)
    • new product Sylvant (siltuximab)
    • new product Zykadia (ceritinib)
    • new product Zontivity (vorapaxar)
    • new product Entyvio (vedolizumab)
    • new product Dalvance (dalbavancin)
    • new product Omidria (ketorolac and phenylephrine)
    • new product Jublia (efinaconazole)
    • new product Sivextro (tedizolid)
    • new product Beleodaq (belinostat)
    • new product Kerydin (tavaborole)
    • new product Zydelig (idelalisib)
    • new product Striverdi Respimat (olodaterol)
    • new product Belsomra (suvorexant)
    • new product Triumeq (abacavir, dolutegravir and lamivudine)
    • new product Keytruda (pembrolizumab)
    • new product Trulicity (dulaglutide)
    • new product Iluvien (fluocinolone acetonide)
    • new product Vitekta (elvitegravir)
    • new product Tybost (cobicistat)
    • new product Harvoni (ledipasvir and sofosbuvir)
    • new product Akynzeo (netupitant and palonosetron)
    • new product Lumason (sulfur hexafluoride lipid microsphere)
    • new product Blincyto (blinatumomab)
    • new product Xtoro (finafloxacin)
    • new product Zerbaxa (ceftolozane and tazobactam)
    • new product Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir)
    • new product Lynparza (olaparib)
    • new product Natpara (recombinant human parathyroid hormone)
    • new product Evotaz (atazanavir and cobicistat)
    • new product Prezcobix (cobicistat and darunavir)
    • new product Glyxambi (empagliflozin and linagliptin)
    • new product Pazeo (olopatadine hydrochloride)
    • new product Ibrance (palbociclib)
    • new product Farydak (panobinostat)
    • new product Avycaz (avibactam and ceftazidime)
    • new product Cresemba (isavuconazonium)
    • new product Unituxin (dinutuximab)
    • new product Orkambi (ivacaftor and lumacaftor)
    • new product Entresto (sacubitril and valsartan)
    • new product Rexulti (brexpiprazole)
    • new product Technivie (ombitasvir, paritaprevir and ritonavir)
    • new product Odomzo (sonidegib)
    • new product Daklinza (daclatasvir)
    • new product Praluent (alirocumab)
    • new product Repatha (evolocumab)
    • new product Varubi (rolapitant)
    • new product Xuriden (uridine triacetate)
    • new product Vraylar (cariprazine)
    • new product Imlygic (talimogene laherparepvec)
    • new product Nuplazid (pimavanserin)
    • new product Tecentriq (atezolizumab)
    • new product Axumin (fluciclovine F 18)